|
|
Volumn , Issue 547, 2002, Pages 11-14
|
|
Clinical impact of using chemoradiotherapy as a primary treatment for hypopharyngeal cancer
a
|
|
Author keywords
Complete remission; Preservation of larynx; Quality of life; Salvage
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CISPLATIN;
UFT;
ANTINEOPLASTIC ANTIMETABOLITE;
RADIOSENSITIZING AGENT;
TEGAFUR;
URACIL;
CANCER ADJUVANT THERAPY;
CANCER COMBINATION CHEMOTHERAPY;
CANCER RADIOTHERAPY;
CANCER REGRESSION;
CANCER SURGERY;
CANCER SURVIVAL;
CONFERENCE PAPER;
CONTROLLED STUDY;
HEAD AND NECK CANCER;
HUMAN;
HYPOPHARYNX CANCER;
LARYNX;
MAJOR CLINICAL STUDY;
NECK DISSECTION;
PREOPERATIVE TREATMENT;
PRIORITY JOURNAL;
QUALITY OF LIFE;
REMISSION;
TREATMENT OUTCOME;
ADJUVANT CHEMOTHERAPY;
ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
DRUG COMBINATION;
DRUG EFFECT;
FEMALE;
FOLLOW UP;
HYPOPHARYNX TUMOR;
MALE;
MORTALITY;
OUTCOME ASSESSMENT;
PHARYNX;
RADIATION DOSE;
RADIATION EXPOSURE;
SURVIVAL RATE;
TIME;
ANTIMETABOLITES, ANTINEOPLASTIC;
CHEMOTHERAPY, ADJUVANT;
CISPLATIN;
DRUG THERAPY, COMBINATION;
FEMALE;
FOLLOW-UP STUDIES;
HUMANS;
HYPOPHARYNGEAL NEOPLASMS;
MALE;
OUTCOME ASSESSMENT (HEALTH CARE);
PHARYNX;
RADIATION-SENSITIZING AGENTS;
RADIOTHERAPY DOSAGE;
SURVIVAL RATE;
TEGAFUR;
TIME FACTORS;
URACIL;
|
|
EID: 0035992898
PISSN: 03655237
EISSN: None
Source Type: Journal
DOI: 10.1080/000164802760057491 Document Type: Conference Paper |
|
Times cited : (17)
|
|
References (10)
|
